Accelerating FDA Submissions Through AI-Assisted Module Drafting to Reduce Risk & Enhance Regulatory Efficiency
- Shortening submission timelines and expanding legal and regulatory capacity by embedding AI into FDA module drafting for a live Phase 2 asset
- Mitigating hallucination, confidentiality, and trade-secret exposure through structured guardrails, validation workflows, and disciplined human oversight
- Demonstrating measurable ROI through a real-world implementation with an external AI partner while preserving defensibility and data integrity